RVTY
VENTE TOTALE: 85 titres (~9306 USD)
- Insiders
- Gonzales Anita
- Total bought
- —
- Total sold
- $9,306
- Last activity
- 2026-07-20
- Last synced
-
2026-08-04 10:23:03
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-07
RVTY presents a weak combined profile with deteriorating fundamentals (liquidity score 45, fundamentals trend score 35) and a modest catalyst signal (score 35, confidence 0.55) driven by mixed congressional trades…
The first sentence of the analysis written for RVTY on 2026-09-07 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-28 | 2024-12-29 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 53.1% | 48.0% | 48.1% | 53.2% | 59.6% | |
| Ebit Margin | 12.6% | 15.0% | 10.2% | 22.8% | 34.1% | |
| Ebitda Margin | 23.2% | 30.5% | 25.9% | 35.7% | 42.2% | |
| Operating Profit Margin | 12.5% | 14.9% | 14.5% | 23.6% | 35.0% | |
| Pretax Profit Margin | 9.4% | 11.5% | 6.7% | 19.7% | 31.4% | |
| Continuous Operations Profit Margin | 8.5% | 10.3% | 6.5% | 15.5% | 23.2% | |
| Net Profit Margin | 8.5% | 10.7% | -4.3% | 17.2% | 24.6% | |
| Bottom Line Profit Margin | 8.5% | 10.7% | -4.3% | 17.2% | 24.6% | |
| Current Ratio | 1.682 | 3.598 | 2.069 | 2.129 | 2.011 | |
| Quick Ratio | 1.397 | 3.035 | 1.774 | 1.867 | 1.660 | |
| Solvency Ratio | 0.111 | 0.153 | 0.055 | 0.148 | 0.160 | |
| Cash Ratio | 0.691 | 1.781 | 0.630 | 0.294 | 0.497 | |
| Price To Earnings Ratio | 46.688 | 46.187 | -115.148 | 31.079 | 24.764 | |
| Price To Earnings Growth Ratio | -3.410 | -0.131 | 0.951 | -0.699 | 1.016 | |
| Forward Price To Earnings Growth Ratio | -3.410 | -0.131 | 0.951 | -0.699 | 1.016 | |
| Price To Earnings Diluted Ratio | 46.688 | 46.187 | -115.148 | 31.145 | 24.872 | |
| Price To Earnings Diluted Growth Ratio | -3.410 | -0.131 | 0.951 | -0.703 | 1.017 | |
| Price To Book Ratio | 1.516 | 1.782 | 1.731 | 2.396 | 3.271 | |
| Price To Sales Ratio | 3.849 | 4.960 | 4.956 | 5.341 | 6.102 | |
| Price To Free Cash Flow Ratio | 21.631 | 25.227 | 1,376.352 | 29.771 | 17.631 | |
| Price To Operating Cash Flow Ratio | 18.898 | 21.748 | 149.349 | 26.021 | 16.556 | |
| Debt To Assets Ratio | 0.289 | 0.268 | 0.300 | 0.325 | 0.344 | |
| Debt To Equity Ratio | 0.485 | 0.434 | 0.516 | 0.622 | 0.723 | |
| Debt To Capital Ratio | 0.327 | 0.303 | 0.341 | 0.384 | 0.420 | |
| Long Term Debt To Capital Ratio | 0.277 | 0.291 | 0.288 | 0.347 | 0.411 | |
| Financial Leverage Ratio | 1.678 | 1.616 | 1.723 | 1.914 | 2.101 | |
| Working Capital Turnover Ratio | 2.193 | 1.697 | 1.670 | 2.229 | 4.221 | |
| Operating Cash Flow Ratio | 0.437 | 0.962 | 0.063 | 0.440 | 1.162 | |
| Operating Cash Flow Sales Ratio | 0.204 | 0.228 | 0.033 | 0.205 | 0.369 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.874 | 0.862 | 0.109 | 0.874 | 0.939 | |
| Debt Service Coverage Ratio | 0.935 | 8.363 | 0.865 | 1.815 | 12.250 | |
| Interest Coverage Ratio | 3.869 | 4.264 | 4.043 | 7.514 | 13.121 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.988 | 2,596.277 | 0.126 | 1.444 | 332.724 | |
| Operating Cash Flow Coverage Ratio | 0.165 | 0.189 | 0.022 | 0.148 | 0.273 | |
| Capital Expenditure Coverage Ratio | 7.913 | 7.251 | 1.122 | 7.939 | 16.400 | |
| Dividend Paid And Capex Coverage Ratio | 5.472 | 5.188 | 0.785 | 5.619 | 11.916 | |
| Dividend Payout Ratio | 0.136 | 0.116 | -0.295 | 0.062 | 0.034 | |
| Enterprise Value Multiple | 20.507 | 18.835 | 23.521 | 18.457 | 17.261 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 53.1% | ▲5.1% | ▲0.7% |
| Ebit Margin | 12.6% | ▼-2.4% | ▼-6.3% |
| Ebitda Margin | 23.2% | ▼-7.3% | ▼-8.3% |
| Operating Profit Margin | 12.5% | ▼-2.4% | ▼-7.6% |
| Pretax Profit Margin | 9.4% | ▼-2.1% | ▼-6.3% |
| Continuous Operations Profit Margin | 8.5% | ▼-1.8% | ▼-4.3% |
| Net Profit Margin | 8.5% | ▼-2.3% | ▼-2.9% |
| Bottom Line Profit Margin | 8.5% | ▼-2.3% | ▼-2.9% |
| Current Ratio | 1.682 | ▼-1.915 | ▼-0.615 |
| Quick Ratio | 1.397 | ▼-1.637 | ▼-0.549 |
| Solvency Ratio | 0.111 | ▼-0.043 | ▼-0.015 |
| Cash Ratio | 0.691 | ▼-1.090 | ▼-0.088 |
| Price To Earnings Ratio | 46.688 | ▲0.501 | ▲39.974 |
| Price To Earnings Growth Ratio | -3.410 | ▼-3.279 | ▼-2.955 |
| Forward Price To Earnings Growth Ratio | -3.410 | ▼-3.279 | ▼-2.955 |
| Price To Earnings Diluted Ratio | 46.688 | ▲0.501 | ▲39.939 |
| Price To Earnings Diluted Growth Ratio | -3.410 | ▼-3.279 | ▼-2.954 |
| Price To Book Ratio | 1.516 | ▼-0.266 | ▼-0.623 |
| Price To Sales Ratio | 3.849 | ▼-1.110 | ▼-1.192 |
| Price To Free Cash Flow Ratio | 21.631 | ▼-3.595 | ▼-272.491 |
| Price To Operating Cash Flow Ratio | 18.898 | ▼-2.850 | ▼-27.617 |
| Debt To Assets Ratio | 0.289 | ▲0.021 | ▼-0.016 |
| Debt To Equity Ratio | 0.485 | ▲0.051 | ▼-0.071 |
| Debt To Capital Ratio | 0.327 | ▲0.024 | ▼-0.028 |
| Long Term Debt To Capital Ratio | 0.277 | ▼-0.014 | ▼-0.046 |
| Financial Leverage Ratio | 1.678 | ▲0.062 | ▼-0.128 |
| Working Capital Turnover Ratio | 2.193 | ▲0.496 | ▼-0.209 |
| Operating Cash Flow Ratio | 0.437 | ▼-0.525 | ▼-0.176 |
| Operating Cash Flow Sales Ratio | 0.204 | ▼-0.024 | ▼-0.004 |
| Free Cash Flow Operating Cash Flow Ratio | 0.874 | ▲0.011 | ▲0.142 |
| Debt Service Coverage Ratio | 0.935 | ▼-7.428 | ▼-3.910 |
| Interest Coverage Ratio | 3.869 | ▼-0.395 | ▼-2.693 |
| Short Term Operating Cash Flow Coverage Ratio | 0.988 | ▼-2595.289 | ▼-585.324 |
| Operating Cash Flow Coverage Ratio | 0.166 | ▼-0.024 | ▲0.006 |
| Capital Expenditure Coverage Ratio | 7.913 | ▲0.662 | ▼-0.212 |
| Dividend Paid And Capex Coverage Ratio | 5.472 | ▲0.284 | ▼-0.324 |
| Dividend Payout Ratio | 0.136 | ▲0.019 | ▲0.125 |
| Enterprise Value Multiple | 20.507 | ▲1.672 | ▲0.791 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $10.99B | $13.66B | $13.63B | $17.69B | $23.36B | |
| Enterprise value | $13.59B | $15.83B | $16.78B | $21.83B | $27.91B | |
| EV / Sales | 4.76x | 5.75x | 6.10x | 6.59x | 7.29x | |
| EV / Op. cash flow | 23.36x | 25.19x | 183.88x | 32.11x | 19.79x | |
| EV / Free cash flow | 26.74x | 29.22x | 1694.62x | 36.74x | 21.07x | |
| EV / EBITDA | 20.51x | 18.84x | 23.52x | 18.46x | 17.26x | |
| Net debt / EBITDA | 3.92x | 2.57x | 4.42x | 3.50x | 2.82x | |
| Current ratio | 1.68x | 3.60x | 2.07x | 2.13x | 2.01x | |
| Income quality | 2.41x | 2.22x | 0.51x | 1.33x | 1.59x | |
| Graham number | $55 | $58 | — | $77 | $106 | |
| Graham net-net | -$29 | -$24 | -$27 | -$45 | -$56 | |
| Tax burden | 90.1% | 93.6% | -64.7% | 87.3% | 78.4% | |
| Interest burden | 74.4% | 76.7% | 64.9% | 86.2% | 92.2% | |
| Working capital | $908.5M | $1.70B | $1.55B | $1.74B | $1.23B | |
| Invested capital | $10.51B | $11.45B | $11.77B | $12.27B | $12.33B | |
| Return on assets | 2.0% | 2.4% | -0.9% | 4.0% | 6.3% | |
| Operating ROA | 2.9% | 3.2% | 2.9% | 5.4% | 11.7% | |
| Return on tangible assets | 7.5% | 9.0% | -3.0% | 13.3% | 20.7% | |
| Return on equity | 3.3% | 3.9% | -1.5% | 7.7% | 13.2% | |
| Return on invested capital | 2.8% | 3.1% | 3.0% | 4.7% | 7.2% | |
| Return on capital employed | 3.3% | 3.5% | 3.3% | 6.2% | 9.7% | |
| Earnings yield | 2.2% | 2.2% | -0.9% | 3.2% | 4.0% | |
| Free cash flow yield | 4.6% | 4.0% | 0.1% | 3.4% | 5.7% | |
| Capex / Op. cash flow | 12.6% | 13.8% | 89.1% | 12.6% | 6.1% | |
| Capex / Depreciation | 18.1% | 20.3% | 18.8% | 20.1% | 27.6% | |
| Capex / Sales | 2.6% | 3.1% | 3.0% | 2.6% | 2.2% | |
| SG&A / Sales | 33.1% | 26.0% | 25.7% | 22.9% | 19.4% | |
| R&D / Sales | 7.6% | 7.1% | 7.9% | 6.7% | 5.2% | |
| Stock comp / Sales | 0.8% | 1.4% | 1.5% | 1.6% | 0.8% | |
| Intangibles / Total assets | 73.6% | 73.5% | 70.4% | 69.8% | 69.7% | |
| Days sales outstanding | 95d | 84d | 84d | 68d | 68d | |
| Days payables outstanding | 51d | 43d | 52d | 64d | 77d | |
| Operating cycle | 199d | 177d | 193d | 163d | 168d | |
| Cash conversion cycle | 148d | 135d | 141d | 99d | 91d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-19.5%EV / Sales ▼-17.2%EV / EBITDA ▲+8.9%EV / Op. cash flow ▼-1.829Earnings yield +0.000Graham number ▼-2.733
Profitability
Return on equity ▼-0.005Return on assets ▼-0.004Return on invested capital ▼-0.003Return on capital employed ▼-0.002Operating ROA ▼-0.003Income quality ▲+0.192Tax burden ▼-0.035
Efficiency
Days sales outstanding ▲+11.384Days payables outstanding ▲+7.845Operating cycle ▲+21.086Cash conversion cycle ▲+13.241Capex / Sales ▼-0.006R&D / Sales ▲+0.004
Balance-sheet strength
Current ratio ▼-1.915Net debt / EBITDA ▲+1.344Working capital ▼-788007000.000Invested capital ▼-937296000.000Intangibles / Total assets ▲+0.002
Change over 5 years
Valuation
Market cap ▼-52.9%EV / Sales ▼-34.7%EV / EBITDA ▲+18.8%EV / Op. cash flow ▲+3.574Earnings yield ▼-0.018Graham number ▼-50.512
Profitability
Return on equity ▼-0.099Return on assets ▼-0.043Return on invested capital ▼-0.043Return on capital employed ▼-0.064Operating ROA ▼-0.088Income quality ▲+0.826Tax burden ▲+0.117
Efficiency
Days sales outstanding ▲+27.662Days payables outstanding ▼-26.174Operating cycle ▲+30.475Cash conversion cycle ▲+56.649Capex / Sales ▲+0.003R&D / Sales ▲+0.023
Balance-sheet strength
Current ratio ▼-0.329Net debt / EBITDA ▲+1.100Working capital ▼-318535000.000Invested capital ▼-1811888000.000Intangibles / Total assets ▲+0.040
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-05-04 | Gilbert Cisneros | Purchase | $15,001 - $50,000 |
| 2025-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-09-12 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-08-26 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-08-26 | Ro Khanna | Sale | $1,000 - $15,000 |
| 2025-08-13 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-07-23 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-07-22 | Lisa McClain | Sale (Partial) | $1,001 - $15,000 |
| 2025-06-17 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2025-06-11 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-05-28 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-05-28 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-04-08 | Rob Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-02-28 | John Delaney | Sale | $15,001 - $50,000 |
| 2025-02-25 | Rob Bresnahan | Purchase | $1,001 - $15,000 |
| 2024-11-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-06-26 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-08 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-07-19 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Sale | $1,001 - $15,000 |
Recent news
- 2026-07-31 Revvity Board Declares Quarterly Dividend WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 13, 2026 to all shareholders of record at the close of business on October 23, 2026. About Revvity At Revvity, “impossible” is inspiration, and “can''t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows fr.
- 2026-07-30 Revvity to Report Q2 Earnings: What''s in Store for the Stock? Revvity, Inc. RVTY is slated to report second-quarter 2026 results on Aug. 4, before market open.
- 2026-07-28 Revvity (RVTY) Earnings Expected to Grow: What to Know Ahead of Next Week''s Release Revvity (RVTY) doesn''t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 2026-07-28 Bank of Nova Scotia Has $5.13 Million Stock Position in Revvity Inc. $RVTY Bank of Nova Scotia lifted its position in shares of Revvity Inc. (NYSE: RVTY) by 436.4% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 58,546 shares of the company''s stock after buying an additional 47,631 shares during
- 2026-07-24 Revvity Develops High-Throughput T-SPOT.TB Platform for Clinical Labs RVTY''s T-SPOT A201 targets a 2027 launch, promising high-throughput latent TB testing with greater lab efficiency and scalability.
- 2026-07-23 Revvity Announces Development of High-Throughput T-SPOT.TB Automated Platform for Clinical Labs WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the development of the T-SPOT™ A201, a next-generation high-throughput automated platform designed to support the performance advantages of T-SPOT.TB™ testing for large-volume clinical labs, enabling a reliable, accurate solution for latent tuberculosis (TB) detection. Tuberculosis remains a critical global health challenge, with testing demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies.
- 2026-07-22 Revvity to Launch Signals for Startups for Emerging Biotech Companies RVTY''s Signals for Startups gives early-stage biotechs scalable software and guided onboarding to streamline research and support future growth.
- 2026-07-20 Revvity Launches “Signals for Startups” to Help Emerging Biotechs Build Scalable Digital Foundations from Day One WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. announced that its Revvity Signals Software business is launching Signals for Startups, a new program designed to help emerging biotechnology companies adopt scalable informatics capabilities earlier in their growth journey. Built for early-stage biotechs, the program combines access to enterprise-grade Signals software with guided onboarding and best-practice configurations tailored specifically for smaller biotechs to help accelerate innovation,.
- 2026-07-20 Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today published its 2026 Impact Report, highlighting the Company''s sustainability, social and governance strategy, initiatives and performance. The annual report showcases how the Company continues to translate innovation into real-world impact, while embedding responsible and sustainable practices through its operations. "At Revvity, we believe scientific innovation and responsible business practices go hand in hand," said Prahlad Sin.
- 2026-07-08 Revvity to Hold Earnings Call on Tuesday, August 4, 2026 WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its second quarter 2026 financial results prior to market open on Tuesday, August 4, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of.